The European Clinical Research Infrastructures network (ECRIN) is a public, non-profit organization that links scientific partners and networks across Europeto facilitate multinational clinical research. 

ECRIN provide sponsors and investigators with advice, management services and tools to overcome hurdles to multinational trials and enhance collaboration.

ECRIN has been set-up with the aim to address these challenges and to overcome the historical fragmentation of clinical research at European level.

ECRIN's vision is to generate scientific evidence to optimise medical practice. To achieve this vision, ECRIN supports the conduct of multinational clinical research in Europe. By managing and supporting clinical trials across borders, connecting networks, and advising and implementing policy, ECRIN advances knowledge flow, competitiveness and integration in European clinical research. Without excluding industry-sponsored studies, ECRIN focuses its work on the conduct of independent trials, across all disease and topic areas. These trials provide unbiased assessment of preventative, diagnostic and therapeutic interventions that might not otherwise be investigated. Focus areas include:

• Development of innovative health products
• Exploration of new indications for authorised health products
• Comparative assessment of efficacy and safety of approved healthcare strategies

Luxembourg is actually a scientific partner and Dr Jonathan Cimino, from CIEC is the European correspondent for ECRIN in Luxembourg.

CIEC involvement & European Correspondent role

• Support in multinational clinical trials

• Providing information & consultancy: logistical assessments, budget estimation, regulatory & ethics information
• Providing services: feasibilities, regulatory & ethics submissions, monitoring, project management, pharmacovigilance
• Communication between EuCos and the ECRIN coordination office

• Participation in various ECRIN activities (ECRIN Data center audits, quality procedures…)
• Management of clinical studies in Luxembourg and Belgium (regulatory & ethics submissions, management of CRAs (in-house & outsourced), project management, local pharmacovigilance)

LIH involvement in ECRIN studies (ongoing)

HIVACAR (Infectious disease, HIV vaccine): A phase IIa, multicentre, randomized, double-blinded placebo controlled trial to evaluate the safety and tolerability of the combination of a therapeutic vaccine (MVA-B, iHIVARNA01.3 or HIVACAR01) plus 3BNC117 bNAb with romidepsin

PrOOf (Neurology, Intensive Care Unit): Penumbral Rescue by Normobaric O=O Administration in Patients with Acute Ischemic Stroke and Target Mismatch ProFile: A Phase II Proof-of-Concept Trial (PrOOf)

OTBB3 (Pediatry, rare disease): Oxytocin treatment in neonates and infants (babies) with Prader-Willi syndrome: effects of intranasal administrations of oxytocin in infants aged from 0 to 3 months vs placebo on sucking and swallowing.

ImmunAID (Rhumatology): Immunome project consortium for AutoInflammatory Disorders

BETA3 (Cardiology, heart insufficiency): A multicentre, randomised, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease.

POPART: PROPHYLACTIC OROPHARYNGEAL SURFACTANT FOR PRETERM INFANTS: A RANDOMISED TRIAL: A randomised trial of oropharyngeal surfactant versus no intervention at birth for infants born before 29 weeks of gestation to prevent endotracheal intubation for respiratory failure in the first 5 days of life.